New oral anticoagulants in atrial fibrillation.

Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dose adjustment to maintain effects within the therapeutic range. The clinical development pathway for novel anticoagulants often involves evaluation of efficacy and safety in a short-term indication, such as the prevention of venous thrombo-embolism (VTE), followed by longer-term VTE treatment studies, and finally chronic indications, including stroke prevention studies in patients with AF. The coagulation pathway provides many targets for novel anticoagulants, including Factor Xa (FXa) and Factor IIa (thrombin). Numerous oral, direct FXa inhibitors are in various stages of clinical development, including rivaroxaban, LY517717, YM150, DU-176b, apixaban, and betrixaban, and are anticipated to overcome the limitations of VKAs. Dabigatran is the only oral direct thrombin inhibitor in late-stage development. Studies of these agents for stroke prevention in patients with AF are planned or ongoing. If approved, they may represent the next generation of anticoagulants, by providing new therapeutic options for stroke prevention in patients with AF.

[1]  R. Blumenthal,et al.  Vascular disease, hypertension, and prevention. , 2006, Journal of the American College of Cardiology.

[2]  A. Dmitrienko,et al.  A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement , 2007, Journal of thrombosis and haemostasis : JTH.

[3]  H. Büller,et al.  Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) – an oral, direct factor Xa inhibitor , 2007, Thrombosis and Haemostasis.

[4]  M. Gent,et al.  BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study , 2005, Journal of thrombosis and haemostasis : JTH.

[5]  M. Ezekowitz,et al.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). , 2007, The American journal of cardiology.

[6]  M. Prins,et al.  YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study. , 2005 .

[7]  J. Riancho,et al.  Atrial fibrillation as a risk factor for stroke recurrence. , 2003, The American journal of medicine.

[8]  K. Fahrbach,et al.  Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. , 2004, Chest.

[9]  O. Dahl.  Orthopaedic Surgery as a Model for Drug Development in Thrombosis , 2004, Drugs.

[10]  T. Shibano,et al.  Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor. , 2004 .

[11]  M. Blombäck,et al.  Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. , 2007, Thrombosis research.

[12]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[13]  B. Eriksson,et al.  Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement , 2005, Journal of clinical pharmacology.

[14]  G. Pineo,et al.  A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators. , 2006 .

[15]  V. Hasselblad,et al.  Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. , 2006, Thrombosis research.

[16]  H. Büller,et al.  Direct thrombin inhibitors. , 2005, The New England journal of medicine.

[17]  W. Mueck,et al.  Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin , 2006, Journal of clinical pharmacology.

[18]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[19]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[20]  W. Mueck,et al.  Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. , 2007, British journal of clinical pharmacology.

[21]  B. Eriksson,et al.  A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement , 2006, Circulation.

[22]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[23]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[24]  J. Hirsh.  Heparin and low-molecular weight heparins , 1992 .

[25]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[26]  W. Mueck,et al.  Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects , 2006, Journal of clinical pharmacology.

[27]  G. Wensing,et al.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor , 2005, Clinical pharmacology and therapeutics.

[28]  A. Planès,et al.  Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[29]  H. R. Büller,et al.  Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis , 2004 .

[30]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[31]  C. Weinz,et al.  Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  S. Aaron,et al.  Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty , 1998, Thrombosis and Haemostasis.

[33]  I. Trocóniz,et al.  Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery , 2007, Journal of clinical pharmacology.

[34]  A Laupacis,et al.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. , 1995, Archives of internal medicine.

[35]  C. Hermans,et al.  Review of the rebound phenomenon in new anticoagulant treatments , 2006, Current medical research and opinion.

[36]  B. Eriksson,et al.  Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. , 2007, Thrombosis research.

[37]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[38]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.

[39]  K. Krueger,et al.  A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR. , 2005 .

[40]  Sum Lam,et al.  Rivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism , 2009, Cardiology in review.

[41]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[42]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[43]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[44]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[45]  S. Hanson,et al.  Animal Models of Thrombosis Help Predict the Human Therapeutic Concentration of PRT54021, a Potent Oral Factor Xa Inhibitor. , 2006 .

[46]  A. Tersteegen,et al.  RIVAROXABAN - AN ORAL, DIRECT FACTOR XA INHIBITOR - BINDS RAPIDLY TO FACTOR XA , 2007 .

[47]  M. Prins,et al.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study , 2008, Journal of thrombosis and haemostasis : JTH.

[48]  B. Psaty,et al.  Newly detected atrial fibrillation and compliance with antithrombotic guidelines. , 2007, Archives of internal medicine.

[49]  F. Veglia,et al.  Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. , 2005, European heart journal.

[50]  R. Leadley.  Coagulation factor Xa inhibition: biological background and rationale. , 2001, Current topics in medicinal chemistry.

[51]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[52]  J. Weitz,et al.  Emerging anticoagulants for the treatment of venous thromboembolism , 2006, Thrombosis and Haemostasis.

[53]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[54]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[55]  P. Sprengeler,et al.  Perspectives on factor Xa inhibition. , 2001, Current medicinal chemistry.

[56]  W. Mueck,et al.  The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. , 2006 .

[57]  Persist investigators.  A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.

[58]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[59]  K. Schlemmer,et al.  In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor , 2005, Journal of thrombosis and haemostasis : JTH.

[60]  Leon Poller,et al.  Quality assessment of coaguchek monitors: comparative analysis of the ECAA and conventional external QA , 2007 .

[61]  H. Gold,et al.  Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. , 1993, Journal of the American College of Cardiology.

[62]  R. Levine,et al.  Atrial Fibrillation Is Associated with Severe Acute Ischemic Stroke , 2003, Neuroepidemiology.

[63]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[64]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[65]  R. Hart,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 2000 .

[66]  D. Kubitza,et al.  Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases , 2006, Expert opinion on investigational drugs.

[67]  Po Box.  Ximelagatran versus low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial , 2005 .

[68]  D. Pepper,et al.  Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4) , 1992, British journal of haematology.

[69]  S. Ederhy.  Idraparinux versus standard therapy for venous thromboembolic disease. , 2007 .

[70]  E. Antman,et al.  Selection of the optimal reperfusion strategy for STEMI: does time matter? , 2006, European heart journal.

[71]  B. Eriksson,et al.  Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.

[72]  G. Pineo,et al.  The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[73]  J. Weitz,et al.  The status of new anticoagulants , 2006, British journal of haematology.

[74]  R. Peters,et al.  Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. , 2002, Journal of the American College of Cardiology.

[75]  Y. Iwatsuki,et al.  Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor. , 2006 .

[76]  Palle Petersen,et al.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.